Aktis Oncology, Inc.

As of June 30, 2026, Aktis Oncology, Inc. carries a market capitalization of 1.78B, placing it among publicly traded companies globally. Its enterprise value stands at 1.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aktis Oncology, Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Aktis Oncology, Inc. has 55.32M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 168.10, and the price-to-book ratio stands at 3.68.

These figures are as of June 30, 2026. The EV/Sales ratio of 126.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.28B versus a market cap of 1.78B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Aktis Oncology, Inc. maintains a current ratio of 16.33, meaning it holds 16.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 127,341.77 in revenue per employee across its workforce of 79.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on November 6, 2026. The 50-day moving average sits at 19.49, while the 200-day moving average is 20.88.

Over the twelve months ended June 30, 2026, Aktis Oncology, Inc. generated 10.06M in revenue and converted that into -73.14M in net income, yielding earnings per share of -1.39. EBITDA reached -84.36M, while operating income came in at -87.18M.

As of June 30, 2026, Aktis Oncology, Inc. holds 517.32M in cash and equivalents against 11.24M in total debt, resulting in a net debt position of -82.49M. Total book value stands at 484.84M, with working capital of 492.41M providing operational flexibility.

Aktis Oncology, Inc. produced -75.29M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.27M in capital expenditures, free cash flow totaled -84.57M - equivalent to -1.61 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -866.63 and net profit margin of -727.04 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.00: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.90, meaning Aktis Oncology, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Aktis Oncology, Inc. has an Altman Z-Score of 14.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.